NCT01173016View on ClinicalTrials.gov

Administration of IV Laronidase Post Bone Marrow Transplant in Hurler

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 29, 2012

Primary Completion Date

March 4, 2016

Study Completion Date

March 4, 2016

Conditions
Hurler Syndrome
Interventions
DRUG

Laronidase

Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT01173016 - Administration of IV Laronidase Post Bone Marrow Transplant in Hurler | Biotech Hunter | Biotech Hunter